May 06, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences®...

recent articles

June 2, 2020 | 1pm EDT  - Register Now The acquisition and interpretation of digital, whole slide images (WSI) of microscope slides for diagnosis has potential to transform pathology practice. Because WSIs differ in format and method of...

How does NeuroScience Associates support amyotrophic lateral sclerosis (ALS) research? We are a specialty CRO that works with scientists across a broad spectrum of research, some of which is focused on ALS. We utilize our expertise in study...

Explore Dr. David Rimm’s strategy for biomarker discovery Find out why Dr. Rimm’s work suggests that a subset of cells that have lost beta-catenin expression may be associated with non-response. In this seminar recording from USCAP...

Albuquerque, NM and Reston, VA– May 19, 2020 – Indica Labs, a leading provider of computational pathology software, and Octo, a premiere information technology systems provider to the U.S. Federal Government, are pleased to announce the...

OR

platinum partners

gold partners

Silver Partners

Media Partners